The Overview of Studies on Huperzine A: A Natural Drug for the Treatment of Alzheimer's Disease

Medicinal Chemistry of Bioactive Natural Products

Volumn , Issue , 2006, Pages 143-182

  Zhu, Da Yuan ^a   Tan, Chang Heng ^a   Li, Yi Ming ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's Disease; Clinical trial; Huperzine A; Pharmacology; Plant Resource; Structural biology; Synthesis; ZT 1

Indexed keywords

EID: 34247588402     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471739340.ch4     Document Type: Chapter

References (162)

1. Liu, J. S.; Zhu, Y. L.; Yu, C. M.; Zhou, Y. Z.; Han, Y. Y.; Wu, F. W.; Qi, B. F. The structures of huperzines A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can. J. Chem., 1986, 64: 837-839.
2. Xu, Z. L.; Chu, B. M.; Luan, X. H.; Wu, W. Z.; Cai, D. G. Structural identification of Fordine. Med. J. Chinese PLA (in Chinese), 1985, 10(4): 263-264.
3. Wang, Y. E.; Yue, D. X.; Tang, X. C. Anticholinesterase activity of huperzine A. Acta Pharmacol. Sin., 1986, 7(2): 110-113.
4. Tang, X. C.; He, X. C.; Bai, D. L. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs Future, 1999, 24(6): 647-663.
5. Tang, X. C.; Han, Y. F. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev., 1999, 5 (3): 281-300.
6. Kozikowski, A. P.; Tuckmantel W. Chemistry, pharmacology, and clinical efficacy of chinese nootropic agent huperzine A. Acc. Chem. Res., 1999, 32: 641-650.
7. Bai, D. L.; Tang, X. C.; He, X. C. Huperzine A, potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem., 2000, 7: 355-374.
8. Zeng, F. X.; Jiang, H. L.; Yang, Y. S.; Chen, K. X.; Ji, R. Y. Progress in synthesis and structural modification of huperzine A. Prog. Chem., 2000, 12 (1): 63-76.
9. Zangara, A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmarcol. Biochem. Behav., 2003, 75 (3): 675-686.
10. Jiang, H. L.; Bai, D. L.; Luo, X. M. Progress in clinic, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. Curr. Med. Chem., 2003, 10: 2231-2252.
11. Ghiso, J.; Frangione, B. Amyloidosis and Alzheimer's disease. Adv. Drug Deliver Rev., 2002, 54: 1539-1551.
12. Farlow, M.; Gracon, S. I.; Hershey, L. A.; Lewis, K.W.; Sadowsky, C. H.; DolanUreno, J. A controlled trial of tacrine in Alzheimer's disease. JAMA, 1992, 268: 2523-2529.
13. Knapp, M. J.; Knopman, D. S.; Solomon, P. R.; Pendlebury,W.W.; Davis, C. S.; Gracon, S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA, 1994, 271: 985-991.
14. Rogers, S. L.; Farlow, M. R.; Doody, R. S.; Mohs, R.; Friedhoff, L.T. A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 1998, 50 (1): 136-145.
15. Zhou, H.; Jiang, S. H.; Tan, C. H.; Wang, B. D.; Zhu, D. Y. New epoxyserratanes from Huperzia serrata. Planta Med., 2003, 69 (1): 91-94.
16. Tong, X. T.; Tan, C. H.; Zhou, H.; Jiang, S. H.; Ma, X. Q.; Zhu, D. Y. Triterpenoids constituents of Huperzia miyoshiana. Chinese J. Chem., 2003, 21(10): 1364-1368
17. Zhou, H.; Tan, C. H.; Jiang, S. H.; Zhu, D. Y. Serratenetype triterpenoids from Huperzia serrata. J. Nat. Prod., 2003, 66: 1328-1332.
18. Manske, R. H. F. In Manske, R. H. F., editor. The Alkaloids, vol. 5. New York: Academic Press; 1955, 295-300.
19. Manske, R. H. F. In Manske, R. H. F., editor. The Alkaloids, vol. 7. New York: Academic Press; 1960, 505-507.
20. MacLean, D. B. In Manske, R. H. F., editor. The Alkaloids, vol. 10. New York: Academic Press; 1968, 305-382.
21. MacLean, D. B. In Manske, R. H. F., editor. The Alkaloids, vol. 14. New York: Academic Press; 1973, 348-406.
22. Blumenkopf, T. A.; Heathcock, C. H. In Pelletier, S.W., The Alkaloids, vol. 3. New York: Academic Press; 1983, 185-240.
23. Ayer, W. A. The Lycopodium alkaloids. Nat. Prod. Rep., 1991, 8: 455-463.
24. Ayer, W. A.; Trifonov, L. S. In Cordell, G. A.; Brossi, A., editors. The Alkaloids: Chemistry and Pharmacology, vol. 45. New York: Academic Press; 1994, 233-266.
25. Tan, C. H.; Zhu, D. Y. The progress in the research of Lycopodium alkaloids. Chin. J. Nat. Med. (in Chinese), 2003, 1: 1-7.
26. Yu, C. M.; Shen, W. Z.; Han, J. W.; Chen, Y. C.; Zhu, Y. L. Studies on the alkaloids of Chinese medicine, Lycopodium serratum. Acta Pharm. Sin., 1982, 17 (10): 795-797.
27. Geib, S. J.; Tuckmantel, W.; Kozikowski, A. P. Huperzine A, a potent acetylcholinesterase inhibitor of use in the treatment of Alzheimer's disease. Acta Crystallogr. C, 1991, 47: 824-827.
28. Valenta, Z.; Yoshimura. H.; Rogers, E. F.; Ternbah, M.; Wiesner, K. The structure of selagine. Tetrahedron Lett., 1960, 1 (31): 26-33.
29. Chen, C. H.; Lee, S. S. Studies on the bioactive Lycopodium alkaloid-the structure and activity of isoselagine from Lycopodium serratum var. longipetiolatum. J. Taiwan Pharm. Assoc., 1984, 36: 1-7.
30. Sun, C. M.; Ho, L. K.; Sun, M. L. Revised stereochemistry of so-called isoselagine and spectroscopic analysis of 6a-hydroxylycopodine from Lycopodium serratum var. longipetiolatum. Planta Med., 1993, 59: 467-471.
31. Ainge, G. D.; Lorimer, S. D.; Gerard, P. J.; Ruf, L. D. Insecticidal activity of Huperzine A from the New Zealand clubmoss, Lycopodium varium. J. Agr. Food Chem., 2002, 50 (3): 491-494.
32. Ma, X. Q. Ph.D thesis. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1997.
33. Ma, X. Q.; Jiang, S. H.; Zhu, D. Y. Alkaloid patterns in huperzia and some related genera of Lycopodiaceae Sensu Lato occuring in China and their contribution to classification. Biochem. Syst. Ecol., 1998, 26: 723-727.
34. Chu, B. M.; Li, J. Applied high performed thin-layer scanning method to detect the content of fordine of 14 Lycopodium plants. Trad. Chin. Herbs, 1986, 17 (8): 109-110.
35. Ellman, G. L.; Courtney, K. D.; Andre, V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7: 88-95.
36. Cheng, D. H. Ren, H.; Tang, X. C. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport, 1996, 8: 97-101.
37. Scott, L. J.; Gao, K. L. Galantamine, a review of its use in Alzheimer's disease. Drugs, 2000, 60 (5): 1095-1122.
38. Ballard, C. G. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol., 2002, 47: 64-70.
39. Guillozet, A.; Smiley, J. F.; Mash, D. C.; Mesulam, M. M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol., 1997, 42: 909-918.
40. Cheng, D. H.; Tang, X. C. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol. Biochem. Behav., 1998, 60: 377-386.
41. Tang, X. C.; De Sarno, P.; Sugaya, K.; Giacobini, E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J. Neurosci. Res., 1989, 24: 276-285.
42. Tang, X. C.; Kindel, G. H.; Kozikowski, A. P.; Hanin, I. Comparison of the effects of natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J. Enthnopharmacol., 1994, 44: 147-155.
43. Wang, H.; Tang, X. C. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Acta Pharmacol. Sin., 1998, 19: 27-30.
44. Laganiere, S.; Corey, J.; Tang, X. C.; Wulfert, E.; Hanin, I. Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology, 1991, 30: 763-768.
45. Han, Y. F.; Tang, X. C. Preclinical and clinical progress with huperzine A: a novel acetylcholinesterase inhibitor. In Becker, R.; Giacobini, E., editors. Alzheimer Disease: From Molecular Biology to Therapy. Boston, MA: Birkhaüser; 1996, 245-250.
46. Liu, J.; Zhang, H. Y.; Tang, X. C.; Wang, B.; He, X. C.; Bai, D. L. Effects of synthetic-huperzine A on cholinesterase activities and mouse water maze performance. Acta Pharmacol. Sin., 1998, 19: 413-416.
47. Lu, W. H.; Shou, J.; Tang, X. C. Improving effect of huperzine A on discrimination performance in aged rats and adult rats with experimental cognitive impairment. Acta Pharmacol. Sin., 1988, 9: 11-15.
48. Tang,X. C.; Han,Y. F.; Chen, X. P.; Zhu,X.D. Effects of huperzineAon learning and retrieval process of discrimination performance in rats. Acta Pharmacol. Sin., 1986, 7: 501-511.
49. Tang, X. C.; Xiong, Z. Q.; Qian, B. C.; Zhou, Z. F.; Zhang, C. C. Cognitive improvement by oral huperzine A: a novel acetylcholinesterase inhibitor. In Giacobini, E.; Becker, R., editors. Alzheimer Therapy: Therapeutic Strategies. Boston,MA: Birkhaüser; 1994, 113-119.
50. Wang, T.; Tang, X. C. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur. J. Pharmacol., 1998, 349: 137-142.
51. Xiong, Z. Q.; Tang, X. C. Effects of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol. Biochem. Behav., 1995,51: 415-419.
52. Xiong, Z. Q.; Han, Y. F.; Tang, X. C. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport, 1995, 6: 2221-2224.
53. Xiong, Z. Q.; Cheng, D. H.; Tang, X. C. Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit. Acta Pharmacol. Sin., 1998, 19: 128-132.
54. Ye, J. W.; Cai, J. X.; Wang, L. M.; Tang, X. C. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J. Pharmacol. Exp. Ther., 1999, 288: 814-819.
55. Ye, J.W.; Shang, Y. Z.;Wang, Z. M.; Tang, X. C. Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance. Acta Pharmacol. Sin., 2000, 21 (1): 65-69.
56. Gao, Y.; Tang, X. C.; Guan, L. C.; Kuang, P. Z. Huperzine A reverses scopolamine-and muscimol-induced memory deficits in chick. Acta Pharmacol. Sin., 2000, 21: 1169-1173.
57. Sun, Q. Q.; Xu, S. S.; Pan, J. L.; Guo, H. M.; Cao,W. Q. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacol. Sin., 1999, 20 (7): 601-603.
58. Ou, L. Y.; Tang, X. C.; Cai, J. X. Effect of huperzine A on working memory in reserpineor yohimbine-treated monkeys. Eur. J. Pharmacol., 2001, 433(2-3): 151-156.
59. Filliat, P.; Foquin, A.; Lallement, G. Effects of chronic administration of huperzine A on memory in guinea pigs. Drug Chem. Toxicol., 2002, 25 (1): 9-24.
60. Schmidt, B. H.; Van Der Staay, F. J. Int. J. Geriatr. Psychopharmacol., 1998, 1: 134.
61. Lallement, G.; Baille, V.; Baubichon, D.; Carpentier, P.; Collombet, J. M.; Filliat, P.; Foquin, A.; Four, E.; Masqueliez, C.; Testylier, G.; Tonduli, L.; Dorandeu, F. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology, 2002, 23 (1): 1-5.
62. Ved, H. S.; Koenig, M. L.; Dave, J. R.; Doctor, B. P. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport, 1997, 8 (4): 963-968.
63. Xiao, X. Q.; Zhang, H. Y.; Tang, X. C. Huperzine A attenuates amyloid b-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J. Neurosci. Res., 2002, 67 (1): 30-36.
64. Xiao, X. Q.; Wang, R.; Tang, X. C. Huperzine A and tacrine attenuate b-amyloid peptide-induced oxidative injury. J. Neurosci. Res., 2000, 61 (5): 564-569.
65. Xiao, X. Q.; Wang, R.; Han, Y. F.; Tang, X. C. Protective effects of huperzine A on bamyloid (25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci. Lett., 2000, 286 (3): 155-158.
66. Wang, R.; Zhang, H. Y.; Tang, X. C. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by b-amyloid protein-(1-40) in rat. Eur. J. Pharmacol., 2001, 421 (3): 149-156.
67. Xiao, X. Q.; Yang, J.W.; Tang, X. C. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci. Lett., 1999, 275 (2): 73-76.
68. Wang, R.; Xiao, X. Q.; Tang, X. C. Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport, 2001, 12 (12): 2629-2634.
69. Wang, L. S.; Zhou, J.; Shao, X. M.; Tang, X. C. Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res., 2002, 949(1-2): 162-170.
70. Grunwald, J.; Raveh, L.; Doctor, B. P.; Ashani, Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci., 1994, 54: 991-997.
71. Gordon, R. K.; Nigam, S. V.; Weitz, J. A.; Dave, J. R.; Doctor, B. P.; Ved, H. S. The NMDA receptor ion channel: a site for binding of Huperzine A. J. Appl. Toxicol., 2001, 21(SUPPL 1): S47-S51.
72. Sattler, R.; Tymianski, M. Molecular mechanisms of calcium-dependent excitotoxicity. J. Mol. Med., 2000, 78 (1): 3-13.
73. Choi, D. W. Calcium and excitotoxic neuronal injury. Ann. N Y Acad. Sci., 1994, 747: 162-171.
74. Wang, X. D.; Zhang, J. M.; Yang, H. H.; Hu, G. Y. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol. Sin., 1999, 20: 31-35.
75. Vajda, F. J. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci., 2002, 9 (1): 4-8.
76. Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergman, K.; Gibson, P. H.; Perry, R. H. Correlation of cholinergic abnormalities with senile plaques and mental scores. Br. Med. J., 1978, 2: 1457-1459.
77. Selkoe, D. J.; Abraham, C. R.; Podlisny, M. B.; Duffy, L. K. Isolation of low-molecularweight proteins from amyloid plaque fibers in Alzheimer's disease. J. Neurochem., 1986, 46 (6): 1820-1834.
78. Wang, L. M.; Han, Y. F.; Tang, X. C. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur. J. Pharmacol., 2002, 398 (1): 65-72.
79. Zhou, J.; Fu, Y.; Tang, X. C. Huperzine A protects rat pheochromocytoma cells against oxygen-glucose deprivation. Neuroreport, 2001, 12: 2073-2077.
80. Yan, X. F.; Lu, W. H.; Lou, W. J.; Tang, X. C. Effects of huperzine A and B on skeletal muscle and electroencephalogram. Acta Pharmacol. Sin., 1987, 8: 117-123.
81. Tu, Z. H.;Wu, M. Y. Mutagenicity and comutagenicity of three nootropics: huperzine A, aniracetam and piracetam. New Drugs Clin. Remedies, 1990, 9: 65-68.
82. Zhao, H.W.; Li, X. Y. Ginkgolide A, B, and huperzine A inhibit nitric oxide production from rat C6 and human BT325 glioma cells. Acta Pharmacol. Sin., 1999, 20 (10): 941-943.
83. Li, Y.; Hu, G. Y. Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons. Neurosci. Lett., 2002, 324 (1): 25-28.
84. Li, Y.; Hu, G. Y. Huperzine A inhibits the sustained potassium current in rat dissociated hippocampal neurons. Neurosci. Lett., 2002, 329 (2): 153-156.
85. Galeotti, N.; Ghelardini, C.; Mannelli, L. D.; Bartolini, A. Antinociceptive profile of the natural cholinesterase inhibitor huperzine A. Drug Develop. Res., 2001, 54 (1): 19-26.
86. Zhang, C. L. Therapeutic effects of huperzine A on the aged with memory impairment. New Drugs Clin. Remedies, 1986, 5: 260-262.
87. Zhang, C. L.; Wang, G. Z. Effects of huperzine A tablet on memory. New Drugs Clin. Remedies, 1990, 9: 339-341.
88. Xu, S. S.; Cai, Z. Y.; Qu, Z.W.; Yang, R. M.; Cai, Y. L.;Wang, G. Q.; Su, X. Q.; Zhong, X. S.; Cheng, R. Y.; Xu, W. A.; Li, J. X.; Feng, B. Huperzine A in capsules and tablets for treating patients with Alzheimer disease. Acta Pharmacol. Sin., 1999, 20 (6): 486-490.
89. Xu, S. S.; Gao, Z. X.; Weng, Z.; Du, Z. M.; Xu, W. A.; Yang, J. S.; Zhang, M. L.; Tong, Z. H.; Fang, Y. S.; Chai, X. S. et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Acta Pharmacol. Sin., 1995, 16: 391-395.
90. Cheng, Y. S.; Lu, C. Z.; Ying, Z. L.; Ni, W. Y.; Zhang, C. L.; Sang, G. W. 128 cases of myasthenia gravis treated with huperzine A. New Drugs Clin. Remedies, 1986, 5: 197-199.
91. Mazurek, A. An open label trial of huperzine A in the treatment of Alzheimer's disease. Altern. Ther., 1999, 5 (2): 97-98.
92. Ma, Y. X.; Zhu, Y.; Gu, Y. D.; Yu, Z. Y.; Yu, S. M.; Ye, Y. Z. Double-blind trial of huperzine-A on cognitive deterioration in 314 cases of benign senescent forgetfulness, vascular dementia, and Alzheimer's disease. Ann. NY Acad. Sci., 1998, 854: 506-507.
93. Ma, Y. X.; Zhu, Y.; Gu, Y. D.; Yu, Z. Y.; Yu, S. M.; Ye, Y. Z. Double-blind trail of huperzine-A (HUP) on cognitive impairment and dementia in 314 cases. N-S Arch. Pharmacol., 1998, 358(SUPPL. 1): P35194.
94. Zhang, Z. X.; Wang, X. D.; Chen, Q. T.; Shu, L.; Wang, J. Z.; Shan, G. L. Clinical efficacy and safety of huperzine A in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Chinese Med. J. Peking, 2002, 82 (14): 941-944.
95. Chang, S. Y.; Chen, S. M.; Cao, Q. L.; Liu, P;Wang, F. G.;Wang, Z. X. A clinical study of the effect of huperzine A to improve the ability of verbal recall, retention and repetition in middle-aged and elderly patients with dysmnesia. Herald Med. (in Chinese), 2002, 21 (5): 263-265.
96. Qian, L. G.; Ji, R. Y. A total synthesis of (±)Huperzine A. Tetrahedron Lett., 1989, 30: 2089-2090.
97. Xia, Y.; Kozikowski, A. P. A practical synthesis of the Chinese ''nootropic'' agent huperzine A: a possible lead in the treatment of Alzheimer's disease. J. Am. Chem. Soc., 1989, 111: 4116-4117.
98. Kozikwoski, A. P.; Reddy, E. R.; Miller, C. P. A simplified route to a key intermediate in the synthesis of the Chinese noortropic agent huperzine A. J. Chem. Soc. Perkin. Trans. 1, 1990, 195-197.
99. Campiani, G.; Sun, L. Q.; Kozikowski, A. P.; Aagaard, P.; McKinney, M. A palladiumcatalyzed route to huperzine A and its analogues and their anticholinesrterase activity. J. Org. Chem., 1993, 58: 7660-7669.
100. Kozikowski, A. P.; Campiani, G.; Tuckmantel, W. An approach to open-chain and modified heterocyclic-analogs of the acetylcholinesterase inhibitor huperzine-A through a bicyclo[3.3.1]nonane intermediate. Heterocycles, 1994, 39 (1): 101-116.
101. Camps, P.; Contreras, J.; Fontbardia, M.; Solans, X. Improved synthesis of methyl 7,7-ethylenedioxy-3-methyl-9-oxobicyclo[3.3.1]non-3-ene-1-carboxylate intermediate for the synthesis of huperzine A analogues. Synthetic Commun., 1996, 26 (1): 9-18.
102. Camps, P.; Contreras, J.; El Achab, R.; Morral, J.; Munoz-Torrero, D.; Font-Bardia, M.; Solans, X.; Badia, A.; Vivas, N. M. New syntheses of rac-huperzine A and its rac-7-ethyl-derivative. Evaluation of several huperzine A analogues as acetylcholinesterase inhibitors. Tetrahedron, 2000, 56 (26): 4541-4553.
103. Yamada, F.; Kozikowski, A. P.; Reddy, E. R.; Pang, Y. P.; Miller, J. H.; Mckinney, M. A route to optically pure (-)-huperzine-A-molecular modeling and in vitro pharmacology. J. Am. Chem. Soc., 1991, 113 (12): 4695-4696.
104. Chen, W. P.; Yang, F. Q. Asymmetric total synthesis of optically active huperzine A. Chinese J. Med. Chem., 1995, 5 (1): 10-17.
105. Kaneko, S.; Yoshino, T.; Katoh, T.; Terashima, S. A novel enantioselective synthesis of the key intermediate of (-)-huperzine A employing asymmetric palladium-catalyzed bicycloannulation. Tetrahedron-Asymmetry, 1997, 8 (6): 829-832.
106. He, X. C.; Wang, B.; Bai, D. L. Studies on asymmetric synthesis of huperzine A-1. Palladium-catalyzed asymmetric bicycloannulation of 5,6,7,8-tetrahydro-2-methoxy-6-oxo-5-quinolinecarboxylic esters. Tetrahedron Lett., 1998, 39(5-6): 411-414.
107. He, X. C.; Wang, B.; Yu, G. L.; Bai, D. L. Studies on the asymmetric synthesis of huperzine A. Part 2: highly enantioselective palladium-catalyzed bicycloannulation of the beta-keto-ester using new chiral ferrocenylphosphine ligands. Tetrahedron-Asymmetry, 2001, 12 (23): 3213-3216.
108. Lee, I. Y. C.; Jung, M. H.; Lee, H. W.; Yang, J. Y. Synthesis of huperzine intermediates via Mn(III)-mediated radical cyclization. Tetrahedron Lett., 2002, 43 (13): 2407-2409.
109. Kozikowski, A. P. Synthetic chemistry, neurotransmission and second messengers. J. Heterocyclic Chem., 1990, 27: 97-105.
110. Kozikowski, A. P.; Xia, Y.; Reddy, E. R.; Tuckmantel, W.; Hanin, I.; Tang, X. C. Synthesis of huperzine A and its analogues and their anticholinesterase activity. J. Org. Chem., 1991, 56 (15): 4636-4645.
111. Kozikowski, A. P.; Miller, C. P.; Yamada, F.; Pang, Y. P.; Miller, J. H.; McKinney, M.; Ball, R. G. Delineating the pharmacophoric elements of huperzine A: importance of the unsaturated three-carbon bridge to its AChE inhibitory activity. J. Med. Chem., 1991, 34 (12): 3399-3402.
112. Kozikowski, A. P.; Prakash, K. R. C.; Saxena, A.; Doctor, B. P. Synthesis and biological activity of an optically pure 10-spirocyclopropyl analog of huperzine A. Chem. Commum., 1998, 12: 1287-1288.
113. Campiani, G.; Kozikowski, A. P.; Wang, S.; Ming, L.; Nacci, V.; Saxena, A.; Doctor, B. P. Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring. Bioorg. Med. Chem. Lett., 1998, 8 (11): 1413-1418.
114. Kozikowski, A. P.; Campiani, G., Nacci, V., Sega, A., Saxena, A., Doctor, B. P. An approach to modified heterocyclic analogues of huperzine A and isohuperzine A. Synthesis of the pyrimidone and pyrazole analogues, and their anticholinesterase activity. J. Chem. Soc. Perkin Trans. 1, 1996, 11: 1287-1297.
115. He, X. C.; Wang, Z. Y.; Li, Y. L.; Xu, Z. R.; Bai, D. L. Synthesis of analogues of huperzine A. Chinese Chem. Lett., 1993, 4: 597-600.
116. He, X. C.; Yu, G. L.; Bai, D. L. Studies on analogues of huperzine A for treatment of senile dementia. VI. Asymmetric total synthesis of 14-norhuperzine A and its inhibitory activity of acetylcholinesterase. Acta Pharm. Sin., 2003, 38 (5): 346-349.
117. Kaneko, S.; Nakajima, N.; Shikano, M.; Katoh, T.; Terashima, S. Synthesis and acetylcholinesterase inhibitory activity of fluorinated analogues of huperzine A. Bioorg. Med. Chem. Lett., 1996, 6: 1927-1930.
118. Zeng, F. X.; Jiang, H. L.; Tang, X. C.; Chen, K. X.; Ji, R. Y. Synthesis and acetylcholinesterase inhibitory activity of (±)-14-fluorohuperzine A. Bioorg. Med. Chem. Lett., 1998, 8 (13): 1661-1664.
119. Zhou, G. C.; Zhu, D. Y. Synthesis of 5-substituted analogues of huperzine A. Bioorg. Med. Chem. Lett., 2000, 10 (18): 2055-2057.
120. Hogenauer, K.; Baumann, K.; Mulzer, J. Synthesis of (±)-desamino huperzine A. Tetrahedron Lett., 2000, 41 (48): 9229-9232.
121. Hogenauer, K.; Baumann, K.; Enz, A.; Mulzer, J. Synthesis and acetylcholinesterase inhibition of 5-desamino huperzine A derivatives. Bioorg. Med. Chem. Lett., 2001, 11 (19): 2627-2630.
122. Tang, X. C.; Xu, H.; Feng, J.; Zhou, T. X.; Liu, J. S. Effect of cholinesterase inhibition in vitro by huperzine A analogs. Acta Pharmacol. Sin., 1994, 15 (2): 107-110.
123. Zhu, D. Y.; Tang, X. C., et al. Huperzine A derivatives, their preparation and their use. European Patent, 0 806 416 B1
124. Iong, Z. Q.; Tang, X. C.; Lin, J. L.; Zhu, D. Y. Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment. Acta Pharmacol. Sin., 1995, 16 (1): 21-25.
125. Kozikowski, A. P.; Thiels, E.; Tang, X. C.; Hanin. In Maryanoff, B. E.; Maryanoff, C. A., editors. Advance inMedicinal Chemistry., vol. 1. Greenwich, CT: JAI Press; 1992, 175-205.
126. He, X. C.;Wang, Z. Y.; Li, Y. L.; Bai, D. L. Studies on analogues of huperzine A for the treatment od Alzheimer's disease. I synthesis of 5-substituted aminomethyl-2(1H)-pyridones and 5-substituted amino-5,6,7,8-tetrahydroquinolones. Chinese J. Med. Chem., 1994, 4: 257-262.
127. Fink, D. M.; Bores, G. M.; Effland, R. C.; Huger, F. P.; Kurys, B. E.; Rush, D. K.; Selk, D. E. Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease. J. Med. Chem., 1995, 38 (18): 3645-3651.
128. Wu, B. G. Ph. D thesis, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1996.
129. Wu, B. G.; Zhen, W. P.; Bo, Y. X.; He, X. C.; Bai, D. L. Synthesis of analogues of huperzine A-3. The preparation of some single ring analogues of huperzine A. Chinese Chem. Lett., 1995, 6 (3): 193-196.
130. Wu, B. G.; Bai, D. L. Synthesis of huperzine A analogues. Chinese Pharm. J., 1995, 30(SUPPL.): 63-66.
131. Camps, P.; Contreras, J.; Morral, J.; Munoztorrero, D.; Fontbardia, M.; Solans, X. Synthesis of an 11-unsubstituted analogue of (±)-huperzine A. Tetrahedron, 1999, 55 (28): 8481-8496.
132. Camps, P.; Munoztorrero, D.; Simon, M. Easy access to 4-substituted (±)-huperzine A analogues. Synthetic Commun., 2001, 31 (22): 3507-3516.
133. Badia, A.; Banos, J. E.; Camps, P.; Contreras, J.; Gorbig, D. M.; Munoztorrero, D.; Simon, M.; Vivas, N. M. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Bioorg. Med. Chem., 1998, 6 (4): 427-440.
134. Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Pang, Y. P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9 (16): 2335-2338.
135. Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J. Biol. Chem., 1996, 271: 23646-23649.
136. Carlier, P. R.; Du, D. M.; Han, Y. F.; Liu, J.; Perola, E.; Williams, I. D.; Pang, Y. P. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew. Chem. Int. Ed. Engl., 2000, 39 (10): 1775-1777.
137. Jin, G. Y.; He, X. C.; Zhang, H. Y.; Bai, D. L. Synthesis of alkylene-linked dieters of (-)-huperzine A. Chinese Chem. Lett., 2002, 13 (1): 23-26.
138. Jin, G. Y.; Luo, X. M.; He, X. C.; Jiang, H. L.; Zhang, H. Y.; Bai, D. L. Synthesis and docking studies of alkylene-linked dimers of (-)-huperzine A. Arzneimittel-Forsch, 2003; 53(11): 753-757.
139. Zeng, F. X.; Jiang, H. L.; Yang, Y. S.; Liu, D. X.; Zhang, H. Y.; Chen, K. X.; Ji, R. Y. Synthesis and pharmacological study of huperzine A-E2020 combined compound. Acta Chim. Sin., 2000, 58 (5): 580-587.
140. Liu, J.; Zhang, H. Y.; Wang, L. M.; Tang, X. C. Inhibitory effects of huperzine B on cholinesterase activity in mice. Acta Pharmacol. Sin., 1999, 20 (2): 141-145.
141. Rajendran, V.; Rong, S. B.; Saxena, A.; Doctor, B. P.; Kozikowski, A. P. Synthesis of a hybrid analog of the acetylcholinesterase inhibitors huperzine A and huperzine B. Tetrahedron Lett., 2001, 42 (32): 5359-5361.
142. Rajendran, V.; Saxena, A.; Doctor, B. P.; Kozikowski, A. P. Synthesis of more potent analogues of the acetylcholinesterase inhibitor, huperzine B. Bioorg. Med. Chem. Lett., 2002, 12 (11): 1521-1523.
143. Camps, P.; Contreras, J.; Font-Bardia, M.; Morral, J.; Munoz-Torrero, D.; Solans, X. Enantioselective synthesis of tacrine-huperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assignments by x-ray diffraction analysis. Tetrahedron-Asymmetry, 1998, 9 (5): 835-849.
144. Camps, P.; El Achab, R.; Gorbig, D. M.; Morral, J.; Munoz-Torrero, D.; Badia, A.; Banos, J. E.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, F. J. Synthesis in vitro pharmacology and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J. Med. Chem., 1999, 42 (17): 3227-3242.
145. Raves, M. L.; Harel, M.; Pang, Y. P.; Silman, I.; Kozikowski, A. P.; Sussman, J. L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol., 1997, 4 (1): 57-63.
146. Ashani, Y.; Peggins, J. O.; Doctor, B. P. Mechanism of inhibition of cholinesterases by huperzine-A. Biochem. Biophys. Res. Commun., 1992, 184 (2): 719-726.
147. Saxena, A.; Qian, N. F.; Kovach, I. M.; Kozikowski, A. P.; Pang, Y. P.; Vellom, D. C.; Radic, Z.; Quinn, D.; Taylor, P.; Doctor, B. P. Identification of amino-acid-residues involved in the binding of huperzine-A to cholinesterases. Protein Sci., 1994, 10: 1770-1778.
148. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science, 1991, 253: 872-879.
149. Isralewitz, B.; Gao, M.; Schulten, K. Steered molecular dynamics and mechanical functions of proteins. Curr. Opin. Struc. Biol., 2001, 11: 224-230.
150. Xu, Y. C.; Shen, J. H.; Luo, X.M.; Silman, I.; Sussman, J. L.; Chen, K. X.; Jiang, H. L. How does huperzine A enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations. J. Am. Chem. Soc., 2003, 125 (37): 11340-11349.
151. Kaur, J.; Zhang, M. Q. Molecular modelling and QSAR of reversible acetylcholinesterase inhibitors. Curr. Med. Chem., 2000, 7 (3): 273-294.
152. Camps, P.; Cusack, B.; Mallender, W. D.; El Achab, R.; Morral, J.; Munoz-Torrero, D.; Rosenberry, T. L. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol. Pharmacol., 2000, 57 (2): 409-417.
153. Camps, P.; El Achab, R.; Morral, J.; Munoz-Torrero, D.; Badia, A.; Banos, J. E.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, F. J. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J. Med. Chem., 2000, 43 (24): 4657-4666.
154. Camps, P.; Gomez, E.; Munoz-Torrero, D.; Arno, M. On the regioselectivity of the Friedlander reaction leading to huprines: stereospecific acid-promoted isomerization of syn-huprines to their anti-regioisomers. Tetrahedron-Asymmetry, 2001, 12 (20): 2909-2914.
155. Ros, E.; Aleu, J.; De Aranda, I. G.; Munoz-Torrero, D.; Camps, P.; Badia, A.; Marsal, J.; Solsona, C. The pharmacology of novel acetylcholinesterase inhibitors (±)-huprines Y and X on the Torpedo electric organ. Eur. J. Pharmacol., 2001, 421 (2): 77-84.
156. Camps, P.; Gomez, E.; Munoz-Torrero, D.; Badia, A.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, F. J. Synthesis in vitro pharmacology and molecular modeling of synhuprines as acetylcholinesterase inhibitors. J. Med. Chem., 2001, 44 (26): 4733-4736.
157. Carlier, P. R.; Han, Y. F.; Chow, E. S. H.; Li, C. P. L.;Wang, H.; Lieu, T. X.;Wong, H. S.; Pang, Y. P. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg. Med. Chem., 1999, 7 (2): 351-357.
158. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. P. Natl. Acad. Sci. USA, 1993, 90(19): 9031-9035.
159. Dvir, H.; Wong, D. M.; Harel, M.; Barril, X.; Orozco, M.; Luque, F. J.; Munoz-Torrero, D.; Camps, P.; Rosenberry, T. L.; Silman, I.; Sussman, J. L. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 angstrom resolution: kinetic and molecular dynamic correlates. Biochemistry, 2002, 41 (9): 2970-2981.
160. Felder, C. E.; Harel, M.; Silman, I.; Sussman, J. L. Structure of a complex of the potent and specific inhibitor BW284C51 with Torpedo californica acetylcholinesterase. Acta Crystallogr. D Biol. Crystallogr., 2002, 58: 1765-1771.
161. Wong, D. M.; Greenblatt, H. M.; Dvir, H.; Carlier, P. R.; Han, Y. F.; Pang, Y. P.; Silman, I.; Sussman, J. L. Acetylcholinesterase complexed with bivalent ligands related to huperzine A: experimental evidence for species-dependent protein-ligand complementarity. J. Am. Chem. Soc., 2003, 125 (2): 363-373.
162. Dvir, H.; Jiang, H. L.; Wong, D. M.; Harel, M.; Chetrit, M.; He, X. C.; Jin, G. Y.; Yu, G. L.; Tang, X. C.; Silman, I.; Bai, D. L.; Sussman, J. L. X-ray structures of Torpedo californica acetylcholinesterase complexed with ({thorn})-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry, 2002, 41 (35): 10810-10818.